Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.700
-0.050 (-2.86%)
At close: Aug 13, 2025, 4:00 PM
1.710
+0.010 (0.59%)
After-hours: Aug 13, 2025, 6:33 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $126.38 million as of August 13, 2025. Its market cap has increased by 998.03% in one year.
Market Cap
126.38M
Enterprise Value
34.76M
1-Year Change
998.03%
Ranking
Category
Stock Price
$1.70
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $126.38M, an increase of 25.81%. That is a compound annual growth rate of 5.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 12, 2025 | 130.10M | -40.42% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 570.26B |
| Johnson & Johnson | 418.62B |
| AbbVie | 350.91B |
| AstraZeneca | 229.47B |
| UnitedHealth Group | 228.94B |
| Novartis AG | 228.69B |
| Abbott Laboratories | 228.63B |
| Novo Nordisk | 222.88B |